Skip to main content

Table 5 Comparison of Perceived Efficacy of Extended-Release Naltrexone among SAMHSA-Waivered Physicians to Non-Waivered Physicians. Detailed Table Summary: Waivered providers, as compared to non-waivered ones, were more concerned about the following with respect to extended-release naltrexone to treat OUD: diversion (paired t (31.240) = 3.243, p = 0.003), insufficient training (paired t [40]=4.076, p = 0.000), insufficient time (paired t [38]=5.476, p = 0.000), insufficient staff support (paired t [38]=3.762, p = 0.000), insufficient experience (paired t [37]=5.175, p = 0.000), insufficient resources for patient psychosocial support (paired t [41]=5.855, p = 0.000), and insufficient resources for patient withdrawal management (paired t [41]=5.375, p = 0.000).

From: A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

Perceptions

SAMHSA- waivered Physicians

Non-waivered Physicians

t

df

Mean Difference

Cohen’s d

95% Confidence Interval

p

n

Mean (SD)

n

Mean (SD)

Lower

Upper

Concerns about diversion^

23

1.83 (0.937)

31

1.129 (0.499)

3.243

31.240

0.697

0.934

0.259

1.135

0.003*

Lack of patient interest

21

2.429 (1.248)

32

2.375 (1.008)

0.172

51

0.054

0.048

−0.571

0.678

0.864

Law enforcement oversight^

19

1.790 (0.918)

31

1.226 (0.617)

2.369

28.063

0.564

0.721

0.076

1.051

0.025

Professional licensing board oversight^

18

2.111 (1.231)

31

1.161 (0.523)

3.114

20.614

0.950

1.004

0.315

1.585

0.005

Extended-release naltrexone patients would unfavorably affect my patient mix^

19

1.895 (1.100)

31

1.194 (0.654)

2.518

25.916

0.701

0.775

0.129

1.274

0.018

My co-workers do not support provision of extended-release naltrexone in my practice^

16

1.688 (0.946)

31

1.161 (0.523)

2.067

19.846

0.526

0.689

−0.005

1.057

0.052

Managers/administrators do not support provision of extended-release naltrexone in my practice^

18

2.167 (1.249)

30

1.333 (0.884)

2.483

27.318

0.833

0.771

0.145

1.522

0.019

Reimbursement rates for extended-release naltrexone

16

2.750 (1.125)

29

2.448 (1.298)

0.781

43

0.302

0.249

−0.477

1.081

0.439

Insurance prior authorization requirements^

18

2.944 (0.938)

32

2.750 (1.191)

0.637

42.622

0.194

0.181

−0.421

0.810

0.528

Insufficient training

21

2.762 (1.179)

31

1.548 (0.961)

4.076

50

1.214

1.129

0.616

1.812

0.000*

Insufficient time

22

2.818 (1.097)

31

1.419 (0.765)

5.476

51

1.399

1.479

0.886

1.912

0.000*

Insufficient staff support

22

2.773 (1.110)

31

1.645 (1.050)

3.762

51

1.128

1.044

0.526

1.729

0.000*

Insufficient experience

24

3.042 (1.160)

30

1.567 (0.935)

5.175

52

1.475

1.400

0.903

2.047

0.000*

Insufficient resources for patient psychosocial support within the community or in my practice

24

3.042 (0.955)

31

1.548 (0.925)

5.855

53

1.493

1.589

0.982

2.005

0.000*

Insufficient resources for patient detoxification within the community or in my practice

24

3.250 (0.989)

31

1.742 (1.064)

5.375

53

1.508

1.468

0.945

2.071

0.000*

  1. Notes: Questions about the perceptions of DEA-waivered physicians with non-waivered physicians were compared in these results using independent samples t-test (α = .05, two-tailed level). * indicates significance once a Bonferroni Correction of α = .05/15 = .0033 was applied. ^ indicates that equal variances are not assumed
Back to article page

Substance Abuse Treatment, Prevention, and Policy

ISSN: 1747-597X